Celyad Oncology S.A.
CYAD
Helyezés a részvények között
#31824
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Részvényárfolyam
$0.23358713
Piaci kapitalizáció
$11.04M
Változás (1 nap)
-7.56%
Változás (1 év)
-19.55%
Ország
BE
Kereskedés Celyad Oncology S.A. (CYAD)
Kategória
Healthcare
Celyad Oncology S.A. (CYAD) nyeresége
Nyereség ekkor: 2026 TTM: 0
Celyad Oncology S.A. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége 0. 2026 évben a vállalat 0 nyereséget ért el, megegyezik a 2026 év nyereségéhez, amely 0 volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Celyad Oncology S.A. nyereségtörténete 2010 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2025 | $-769.66K | -87.59% |
| 2024 | $-6.20M | -35.06% |
| 2023 | $-9.55M | -78.46% |
| 2022 | $-44.34M | 43.40% |
| 2021 | $-30.92M | 47.56% |
| 2020 | $-20.95M | -34.80% |
| 2019 | $-32.13M | -25.29% |
| 2018 | $-43.01M | -36.44% |
| 2017 | $-67.67M | 172.38% |
| 2016 | $-24.84M | -21.41% |
| 2015 | $-31.61M | 58.80% |
| 2014 | $-19.91M | 17.25% |
| 2013 | $-16.98M | 497.94% |
| 2012 | $-2.84M | -75.99% |
| 2011 | $-11.82M | 31.79% |
| 2010 | $-8.97M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
